Acute Porphyria Drug Database

J07AL01 - Pneumococcus, Purified Polysaccharides Antigen
Propably not porphyrinogenic
PNP

Rationale
Based on the pharmacokinetics of the pneumococcus, purified polysaccharides antigen vaccine, there are no conceivable porphyrinogenic effects.
Chemical description
Purified polysaccharides antigen of 23 different serotypes.
Therapeutic characteristics
The pneumococcal vaccine is indicated for active immunization for the prevention of pneumococcal disease caused by the 23 serotypes contained in the vaccine in persons over the age of 2, who are at increased risk for pneumococcal disease. The vaccine can be injected subcutaneously or intramuscularly as a single dose.
Metabolism and pharmacokinetics
The pneumococcus vaccine is not metabolized by the cytochrome P450 system.
IPNet drug reports
Uneventful use reported in 1 patient with acute porphyria.

References

  1. Government bodies
  2. Norwegian Institute of Public Health. Vaksinasjonsveilederen. www.fhi.no (updated 13.10.2015). #1857
  3. Summary of Product Characteristics
  4. Norwegian medicines agency. Summary of Product Characteristics (SPC). Pneumovax. #1865

Similar drugs
Explore alternative drugs in similar therapeutic classes J07A / J07AL or go back.

 
© NAPOS 2024
An unhandled error has occurred. Reload 🗙